PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022

US hemophilia market represents the largest sector worldwide

Companies & Markets

28.07.2014 14:38:01 - PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022 - a new market research report on

( - The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and


their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

The US is the largest hemophilia market, due to the high rates of disease diagnosis combined with high rates of primary rFVIII and rFIX prophylaxis among diagnosed severe hemophilia A and B patients. Analysts anticipate that companies such as Baxter, Bayer, Novo Nordisk, CSL Behring and Biogen Idec will be able to command slight premiums over currently marketed recombinant standard of care therapies, thus contributing to overall market growth.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us aims to provide clients with the widest array of reports and market research across all of our 27 industry sectors.’s team of analysts are available to offer clients specific advice on finding relevant information and also purchasing the correct market research reports for their specific business needs. Over 100,000 companies are listed in´s online reports database, providing clients with an extensive coverage not only of company profiles but also of high value and insightful market reports.

Mike King
Phone: 44 0203 086 8600


Disclaimer: If you have any questions regarding information in this article please contact the author. Please do not contact We are not able to assist you. disclaims content contained in this article. is not authorized to give any information about content and not responsible for content posted by third party.
refer this article
Print This Article